Save time and get answers to complex questions with AI chat
Pramlintide fda approval date?Drugpatentwatch trametinib?When does guselkumab patent expire?Motegrity ingredients?When will a generic version of xiaflex be available?
Short answer: There are no brand-name oral Factor B inhibitors approved in the United States yet. If a drug is approved in the U.S. in this class, it would get a brand name at that time. What’s notable in development: - Iptacopan (also referred to by its development code LNP023) is the leading oral Factor B inhibitor in late-stage trials. It’s being studied for conditions like IgA nephropathy and C3 glomerulopathy. It’s an oral pill, and trials have used once-daily dosing in many regimens, which is the main convenience advantage discussed for this agent. However, it has not been approved by the FDA as of now. Other Factor B inhibitors are in earlier development or not yet approved, so they don’t have US brand names either. If you’d like, I can summarize iptacopan’s trial data or compare Factor B inhibitors with other complement-targeting approaches (like Factor D or MASP-2 inhibitors) in terms of convenience and administration.
Other Questions About Oral :